

7

Referências bibliográficas

- [1] JUNQUEIRA, L.; CARNEIRO, J. **Biologia Celular e Molecular**. 8. ed. Rio de Janeiro: Guanabara Koogan, 2005;
- [2] KATSUNG, B. **Farmacologia Básica e Clínica**. 10. ed. Rio de Janeiro: McGraw-hill interamericana, 2010;
- [3] LODISH, H. *et al.* **Molecular Cell Biology**. 6. ed. W.H. Freeman and Company, 2007;
- [4] MACDONALD, F.; FORD, C.; CASSON, A. **Molecular Biology of Cancer**. 2. ed. New York: Bios Scientific Publishers, 2005;
- [5] REIS, A. **Tudo Sobre o Câncer**. INCA – Instituto Nacional do Câncer - Ministério da Saúde, 2007;
- [6] KUMAR, V.; ABBAS, A.; FAUSTO, N. **Robbins e Cotran – Patologia – Bases Patológicas das Doenças**. 8. ed. Rio de Janeiro: Elsevier, 2010;
- [7] HANG, H. P. *et al.* **Pharmacology**. 6. ed. Churchill Livingstone, 2007;
- [8] NORA, B. *et al.* Oncogenes y Genes Supresores de Tumores. **Facultad de Medicina - U.N.N.E.**, 2002;
- [9] RUDDON, R. W. **Cancer Biology**. 4. ed. New York: Oxford University Press, 2007;
- [10] Instituto Nacional de Câncer José Alencar Gomes da Silva. **Estimativa 2012: incidência de câncer no Brasil**. Rio de Janeiro : Inca, 2011;
- [11] HOWLAND, R. D.; MYCEK, M. J. **Farmacologia Ilustrada**. 3. ed. Porto Alegre: Artmed, 2008;

- [12] Ministério da Saúde. **Formulário Terapêutico Nacional**. 2. ed. 2010;
- [13] PRIESTMAN, T. **Cancer Chemotherapy in Clinical Practice**. 1. ed. London: Springer, 2008;
- [14] CRAIG, C. R.; STITZEL, R. E. **Modern Pharmacology with Clinical Applications**. 6. ed. Lippincott Williams & Wilkins, 2003;
- [15] SAYWYERS, C. *et al.* Combining Targeted Drugs to Stop Resistant Tumors. **Science**, v. 331, p. 1542-1545, 2011;
- [16] GOODMAN, A. **As Bases Farmacológicas da Terapêutica**. 11. ed. Rio de Janeiro: McGraw-Hill, 2006;
- [17] DALE, M. M. **Farmacologia Condensada**. 2. ed. Elsevier, 2010;
- [18] ROSENBERG, B. *et al.* Platinum Compounds: a New Class of Potent Antitumour Agents. **Nature**, v. 222, p. 385-386, 1969;
- [19] FARRELL, N. P. **Uses of Inorganic Chemistry in Medicine**. 1. ed. Royal Society of Chemistry, 1999;
- [20] REEDJK, J.; LOHMAN, P. H. M. Cisplatin: Synthesis, Antitumour Activity and Mechanism of Action. **Pharmacy World & Science**, v. 7, n. 5, 2006;
- [21] ATKINS, P. *et al.* **Shriver & Atkins – Química Inorgânica**. 4. ed. Porto Alegre: Bookman, 2008;
- [22] CHVALOVA, K.; BRABEC, V.; KASPARKOVA, J. Mechanism of the Formation of DNA–Protein Cross-Links by Antitumor Cisplatin. **Nucleic Acid Research**, v. 35, n. 6, 2007;
- [23] BRUNTON, L. *et al.* **Goodman and Gilman's – Manual of Pharmacology and Therapeutics**. 1. ed. McGraw-Hill Medical, 2008;
- [24] Complejo Hospitalario Universitario Juan Canalejo. **Guía Básica Farmacoterapéutica**. 5. ed. Comisión de farmácia y terapêutica, 2002;

- [25] KLEIN, R.; BROWN, D.; TURNLEY, A. M. Phenoxodiol Protects Against Cisplatin Induced Neurite Toxicity in a PC-12 Cell Model. **BMC Neuroscience**, v. 8; p. 1-7, 2007;
- [26] BARREIRO, E. J.; FRAGA, C. A. M. **Química medicinal – As Bases Moleculares da Ação dos Fármacos**. 2. ed. Porto Alegre: Artmed, 2008;
- [27] ANTHONY, P. K. **Segredos em Farmacologia**. 1. ed. Porto Alegre: Artmed, 2005;
- [28] KOSTOVA, I. Platinum Complexes as Anticancer Agents. **Recent Patents on Anti-Cancer Drug Discovery**, v.1 p. 1-22, 2006;
- [29] FREZZA, M. *et al.* Novel Metals and Metal Complexes as Platforms for Cancer Therapy. **Current Pharmaceutical Design**, v. 16, p. 1813-1825, 2010;
- [30] PIAGGI, S. *et al.* Glutathione Transferase Omega 1-1 (GSTO1-1) Plays an Anti-Apoptotic Role in Cell Resistance to Cisplatin Toxicity. **Carcinogenesis**, v.31, n. 5, p.804–811, 2010;
- [31] CHEN, D. *et al.* Metal Complexes, their Cellular Targets and Potential for Cancer Therapy. **Current Pharmaceutical Design**, v. 15, p. 777-791, 2009;
- [32] HAMBLEY, T. H. Metal-Based Therapeutics. **Science**, v. 318, n. 1392, 2007;
- [33] RAFIQUE, S. *et al.* Transition Metal Complexes as Potential Therapeutic Agents. **Biotechnology and Molecular Biology Reviews**, v. 5, n. 2, p. 38-45, 2010;
- [34] ZHOU, C. Recent Researches in Metal Supramolecular Complexes as Anticancer Agents. **Anti-Cancer Agents in Medicinal Chemistry**, v. 10, p. 371-395, 2010;
- [35] BRUIJNINCX, P. C. A.; SADLER P. J. New Trends for Metal Complexes with Anticancer Activity. **Current Opinion in Chemical Biology**, v. 12, n. 2, p. 197-206, 2007;

- [36] LIU, H.; SADLER, P. J. Metal Complexes as DNA Intercalators. **Accounts of Chemical Research**, v. 44, N. 5, p. 349–359, 2011;
- [37] REDDY, P. SHILPA, A. Synthesis, Characterization, and DNA-Binding and -Cleavage Properties of Dinuclear CuII_Salophen/Salen Complexes. **Chemistry & Biodiversity**, v. 8, p. 1245-1265, 2011;
- [38] TARDITO, S.; MARCHIO, L. Copper Compounds in Anticancer Strategies. **Current Medicinal Chemistry**, v. 16, p. 1325-1348, 2009;
- [39] MELCHIOR, A. *et al.* Comparative Study of the Hydrolysis of a Third- and a First-Generation Platinum Anticancer Complexes. **Theor. Chem. Acc.** v. 128, p. 627–638, 2011;
- [40] HASS, K. L.; FRANZ, K. J. Application of Metal Coordination Chemistry to Explore and Manipulate Cell Biology. **Chem. Rev.** v. 109, n. 10, p. 4921–4960, 2009;
- [41] ATKINS, P.; JONES, L. **Princípios de Química – Questionando a Vida Moderna e o Meio Ambiente**. 3. ed. Porto Alegre: Bookman, 2006;
- [42] MAHAN, L. K.; ESCOTT-STUMP, S. **Krause: Alimentos, Nutrição e Dietoterapia**, 10 .ed. São Paulo: Roca, 2002;
- [43] BONTEMPO, M. **Suplementos Nutricionais e Produtos Naturais**. 2. ed. São Paulo: Editora Best Seller, 1997;
- [44] LI, Y. *et al.* Potent Inhibition of Protein Tyrosine Phosphatases by Copper Complexes With Multi-Benzimidazole Derivatives. **Biometals**, 2011;
- [45] RAMAKRISHNAN, S. *et al.* Ternary Dinuclear Copper(II) Complexes of a Hydroxybenzamide Ligand with Diimine Coligands: the 5,6-dmp Ligand Enhances DNA Binding and Cleavage and Induces Apoptosis. **Inorganic Chemistry**, v. 50, p. 6458-6571, 2011;
- [46] LI, D. *et al.* DNA binding, oxidative DNA cleavage, cytotoxicity, and apoptosis-inducing activity of copper(II) complexes with 1,4-tpbd (N,N,N',N'-tetrakis(2-yritylmethyl) benzene-1,4-diamine) ligand. **Journal of Inorganic Biochemistry**, v. 105, p. 894–901, 2011;

- [47] TISATO, F. *et al.* Copper in Diseases and Treatments, and Copper-Based Anticancer Strategies. **Medicinal Research Reviews**, v. 30, n. 4, p. 708-749, 2010;
- [48] HINDO, S. S. *et al.* Metals in Anticancer Therapy: Copper(II) Complexes as Inhibitors of the 20S Proteasome. **European Journal of Medicinal Chemistry**, v. 44, p. 4353–4361, 2009;
- [49] XIAO, Y. *et al.* Molecular Study on Copper-Mediated Tumor Proteasome Inhibition and Cell Death. **International Journal of Oncology**, v. 37, p. 81-87, 2010;
- [50] SIGMAN, D. S. *et al.* Oxygen-dependent cleavage of DNA by the 1,10—phenanthroline cuprous complex. **The journal of biological chemical**, v. 254, P. 12269-12272, 1979;
- [51] SILVA, P. P. *et al.* Two New Ternary Complexes of Copper(II) with Tetracycline or Doxycycline and 1,10-Phenanthroline and Their Potential as Antitumoral: Cytotoxicity and DNA Cleavage. **Inorganic Chemistry**, v. 50, p. 6414–6424, 2011;
- [52] SARKER, S.; LUTFUN, N. **Química para Estudantes de Farmácia**. 1. ed. Guanabara Koogan, 2009;
- [53] XIAO, Y. *et al.* L-glutamine Schiff Base Copper Complex as a Proteasome Inhibitor and an Apoptosis Inducer in Human Cancer Cells. **International Journal of Oncology**, v. 33, p. 1073-1079, 2008;
- [54] SHAKIR, M. *et al.* Synthesis, Spectroscopic and Electrochemical Studies of N,N-bis[(E)-2-thienylmethylidene]-1,8-naphthalenediamine and its Cu(II) Complex: DNA Cleavage and Generation of Superoxide Anion. **Journal of Photochemistry and Photobiology B: Biology**, v. 104, p. 449–456, 2011;
- [55] ISPIR, E.; TOROGLU, S.; KAYRALDIZ, A. Syntheses, Characterization, Antimicrobial and Genotoxic Activities of New Schiff Bases and Their Complexes. **Transition Met. Chem.**, v. 33, p. 953-960, 2008;

- [56] ZAHEER, M. *et al.* Synthesis, Characterization, Electrochemistry and Evaluation of Biological Activities of Some Ferrocenyl Schiff Bases. **Appl. Organometal. Chem.**, n. 25, p. 61-69, 2011;
- [57] RUIZ-AZUARA, L. Process to obtain new mixed cooper amino-acidate from methyl phenanthroline complexes to be used as anticancerigenic agents. **US Patent: 5,576,326**. 1996;
- [58] RODRÍGUEZ, A. *et al.* The Metal-coordinated Casiopeína IIIEa Induces the Petite-like Phenotype in *Saccharomyces crevisiae*. **Biometals**, n. 24, p. 1189-1196, 2011;
- [59] JORGE, S. G.; PÉREZ, E. R.; VALLE, M. B. Fragmentación de ADN por Diferentes Casiopeínas. **2º Congreso Nacional de Química Médica**;
- [60] REY, N. A. *et al.* A Promiscuous Dicopper(II) System Promoting the Hydrolysis of Bis(2,4-dinitrophenyl)phosphate: Gaining Mechanistic Insight by Means of Structural and Spectroscopic DFT Studies. **International Journal of Quantum Chemistry**, v. 110, p. 1432–1442, 2010;
- [61] SCOTT, L. E.; ORVIG, C. Medicinal Inorganic Chemistry Approaches to Passivation and Removal of Aberrant Metal Ions in Disease. **Chem. Rev.**, v. 109, p. 4885–4910, 2009;
- [62] PEREIRA, D. G. Importância do Metabolismo no Planejamento De Fármacos. **Química Nova**, v. 30, n. 1, p. 171-177, 2007;
- [63] GU, W. *et al.* Synthesis and Characterization of Gallium Complexes Cearing 4-Alkyl-2,6-Bis(Aryliminomethylene)-Phenol Ligands; Crystal Structure of Dimethyl[4-Methyl-2,6-Bis-(p-Methylphenyliminomethylene)-Phenolato]Gallium. **Inorganica Chimica Acta**, v. 359, p. 1339–1343, 2006;
- [64] SHELDRICK, G. M. **SHELXL-97: Program for the Refinement of Crystal Structures**. University of Gottingen: Germany, 1997;
- [65] FARRUGIA, L. J. ORTEP-3 for Windows – A Version of ORTEP-III with a Graphical User Interface (GUI). **J. Appl. Cryst.**, v. 30, p. 565, 1997;
- [66] <http://cccbDb.nist.gov/>. Acessada em 11 de outubro de 2011;

- [67] Wavefunction, Inc. **Spartan 10 – Tutorial and User's Guide**. 2011;
- [68] BLOCK, J. H.; BEALE, J. M. Jr. **Wilson and Gilvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry**. 11. ed. Lippincott Williams & Wilkins, 2004;
- [69] THOMAS, G. **Medicinal Chemistry – An Introduction**. 2. ed. Wiley, 2007;
- [70] THOMAS, G. **Fundamentals of Medicinal Chemistry**. 1. ed. Wiley, 2003;
- [71] <http://www.organic-chemistry.org/prog/peo/cLogP.html>. Acessado em 19 de novembro de 2011;
- [72] KAPETANOVIC, I.M. Computer-aided drug discovery and development (CADD): in silico-chemico-biological approach. **Chemico-Biological Interactions**, v. 2; n. 171, p. 165–176, 2008;
- [73] <http://www.organic-chemistry.org/prog/peo/tox.html>. Acessado em 1 de março de 2012;
- [74] NOGRADY, T.; WEAVER, D. F. **Medicinal Chemistry – A Molecular and Biochemical Approach**. 3. ed. Oxford University Press, 2005;
- [75] CARLONI, P. ALBER, F. **Quantum Medicinal Chemistry**. Wiley, 2003;
- [76] GRANT, G.H.; RICHARDS, W.G. **Computational Chemistry**. Oxford Science Publication, 1996;
- [77] HEHRE, W.J. **A Guide to Molecular Mechanics and Quantum Chemical Calculations**. Wavefunction, Inc.; 2003;
- [78] PASSAMANI, F. **Modelagem Molecular e Avaliação da Relação Estrutura-Atividade Acoplados a Estudos Farmacocinéticos e Toxicológicos In Silico de Derivados Heterocíclicos com Atividade Antiviral**. 2009. Dissertação (Mestre em Ciências Farmacêuticas) – Curso de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio de Janeiro, Rio de Janeiro;
- [79] <http://www.organic-chemistry.org/prog/peo/mw.html>. Acessado em 19 de novembro de 2011;

- [80] PAJOUHESH, H; LENZ, G.R. Medicinal chemical properties of successful central nervous system drugs. **The Journal of the American Society for Experimental NeuroTherapeutics**, v. 2, n. 4, p. 541-553, 2005;
- [81] GUYTON, A. C.; HALL, J. E. **Physiology**. 11. ed. Philadelphia: Elsevier saunders, 2006;
- [82] C. N. VERANI. **Rational Synthesis and Characterization of Paramagnetic Heteropolynuclear Systems Containing [MA-MB-MC], [MA-MB]₂ and [M₁-2(R)1-2-3] Cores**. 169 p. Dissertation (Doktor der Naturwissenschaft) - Fakultat für Chemie, Ruhr-Universität Bochum, Mulheim an der Ruhr, 2000;
- [83] SMITH, M. B.; MARCH, J. **March's Advanced Organic Chemistry**. 5. ed. Wiley, 2001;
- [84] TODESCHINE, R.; CONSONNI, V. **Handbook of Molecular Descriptors**. 1. ed. Wiley, 2000;
- [85] GOMES, M; REIS, A. **ciências farmacêuticas – uma abordagem em farmácia hospitalar**. 1. ed. Atheneu, 2006;
- [86] ZHANG, G.; MUSGRAVE, C. B. Comparison of DFT Methods for Molecular Orbital Eigenvalue Calculations, **J. Phys. Chem.**, n. 111, p. 1554-1561, 2007;
- [87] SILVERSTEIN, R. M.; WEBSTER F.; KIEMLE, D. **Identificação Espectrométrica de Compostos Orgânicos**. 7. ed. LTC, 2006;
- [88] DEACON G. B.; PHILLIPS, R. J. Relationships Between the Carbon-oxygen Stretching Frequencies of Carboxylato Complexes and the Type of Carboxylate Coordination. **Coordination Chemistry Reviews**, v. 33, p. 227-250, 1980;
- [89] CHANDRAN, K. *et al.* Synthesis and characterization of sodium alkoxides. **Bull. Mater. Sci.**, v. 29, n. 2, p. 173–179, 2006;
- [90] MORAIS, R. S. **Síntese e caracterização de ligantes binucleantes derivados da isoniazida e seus complexos binucleares de cobre(II)**. 2011. Dissertação (Mestre em Química Inorgânica) – Curso de Pós-Graduação em

Química Inorgânica, Pontifícia Universidade Católica do Rio de Janeiro, Rio de Janeiro;

[91] ADDISON, A. W. *et al.* Synthesis, Structure, and Spectroscopic Properties of Copper(II) Compounds containing Nitrogen-Sulphur Donor Ligands; the Crystal and Molecular Structure of Aqua[1,7-bis(N-methylbenzimidazol-2'-yl)-2,6-dithiaheptane]copper(II) Perchlorate. **J. CHEM. SOC. DALTON TRANS**, p. 1349 – 1356, 1984;

[92] MAX, J. J. *et al.* Infrared Titration of Aqueous Sulfuric Acid. **J. Phys. Chem.**, v. 104, p. 2845-2858, 2000;

[93] AZHAGIRI, S. *et al.* Theoretical and experimental studies of vibrational spectra and thermal analysis of 2-nitroaniline and its cation. *J Mol Model*, v. 16, p.87–94, 2009;

[94] Cia. Nitro Química Brasileira. **Ficha de Informação de Segurança de Produto Químico – FISPQ ÁCIDO SULFÚRICO 98%**. 2006.